高级检索
当前位置: 首页 > 详情页

FSH Is Responsible for Androgen Deprivation Therapy-Associated Atherosclerosis in Mice by Exaggerating Endothelial Inflammation and Monocyte Adhesion

文献详情

资源类型:
WOS体系:

收录情况: ◇ SCIE

机构: [1]Peking Univ Peoples Hosp, Dept Urol, 11 Xi Zhi Men S St, Beijing 100044, Peoples R China [2]Peking Univ, Hemorheol Ctr, Sch Basic Med Sci, Dept Physiol & Pathophysiol, 38 Xue Yuan Rd, Beijing 100191, Peoples R China [3]Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing, Peoples R China [4]Univ Elect Sci & Technol China, Sichuan Canc Hosp, Sichuan Canc Ctr, Sch Med,Dept Urol, Chengdu, Peoples R China [5]Peking Univ, Sch Basic Med Sci, Dept Integrat Chinese & Western Med, Beijing, Peoples R China
出处:
ISSN:

关键词: atherosclerosis endothelial cells follicle-stimulating hormone monocytes prostatic neoplasms

摘要:
BACKGROUND:Androgen deprivation therapy (ADT) is the mainstay treatment for advanced prostate cancer. But ADTs with orchiectomy and gonadotropin-releasing hormone (GnRH) agonist are associated with increased risk of cardiovascular diseases, which appears less significant with GnRH antagonist. The difference of follicle-stimulating hormone (FSH) in ADT modalities is hypothesized to be responsible for ADT-associated cardiovascular diseases.METHODS:We administered orchiectomy, GnRH agonist, or GnRH antagonist in male ApoE-/- mice fed with Western diet and manipulated FSH levels by testosterone and FSH supplementation or FSH antibody to investigate the role of FSH elevation on atherosclerosis. By combining lipidomics, in vitro study, and intraluminal FSHR (FSH receptor) inhibition, we delineated the effects of FSH on endothelium and monocytes and the underlying mechanisms.RESULTS:Orchiectomy and GnRH agonist, but not GnRH antagonist, induced long- or short-term FSH elevation and significantly accelerated atherogenesis. In orchiectomized and testosterone-supplemented mice, FSH exposure increased atherosclerosis. In GnRH agonist-treated mice, blocking of short FSH surge by anti-FSH beta antibody greatly alleviated endothelial inflammation and delayed atherogenesis. In GnRH antagonist-treated mice, FSH supplementation aggravated atherogenesis. Mechanistically, FSH, synergizing with TNF-alpha (tumor necrosis factor alpha), exacerbated endothelial inflammation by elevating VCAM-1 (vascular cell adhesion protein 1) expression through the cAMP/PKA (protein kinase A)/CREB (cAMP response element-binding protein)/c-Jun and PI3K (phosphatidylinositol 3 kinase)/AKT (protein kinase B)/GSK-3 beta (glycogen synthase kinase 3 beta)/GATA-6 (GATA-binding protein 6) pathways. In monocytes, FSH upregulated CD29 (cluster of differentiation 29) expression via the PI3K/AKT/GSK-3 beta/SP1 (specificity protein 1) pathway and promoted monocyte-endothelial adhesion both in vitro and in vivo. Importantly, FSHR knockdown by shRNA in endothelium of carotid arteries markedly reduced GnRH agonist-induced endothelial inflammation and atherosclerosis in mice.CONCLUSIONS:FSH is responsible for ADT-associated atherosclerosis by exaggerating endothelial inflammation and promoting monocyte-endothelial adhesion.

基金:
语种:
被引次数:
WOS:
中科院(CAS)分区:
出版当年[2023]版:
大类 | 1 区 医学
小类 | 2 区 血液学 2 区 外周血管病
最新[2023]版:
大类 | 1 区 医学
小类 | 2 区 血液学 2 区 外周血管病
JCR分区:
出版当年[2023]版:
Q1 HEMATOLOGY Q1 PERIPHERAL VASCULAR DISEASE
最新[2023]版:
Q1 HEMATOLOGY Q1 PERIPHERAL VASCULAR DISEASE

影响因子: 最新[2023版] 最新五年平均 出版当年[2023版] 出版当年五年平均 出版前一年[2023版]

第一作者:
第一作者机构: [1]Peking Univ Peoples Hosp, Dept Urol, 11 Xi Zhi Men S St, Beijing 100044, Peoples R China [4]Univ Elect Sci & Technol China, Sichuan Canc Hosp, Sichuan Canc Ctr, Sch Med,Dept Urol, Chengdu, Peoples R China
共同第一作者:
通讯作者:
通讯机构: [2]Peking Univ, Hemorheol Ctr, Sch Basic Med Sci, Dept Physiol & Pathophysiol, 38 Xue Yuan Rd, Beijing 100191, Peoples R China [3]Minist Educ, Key Lab Mol Cardiovasc Sci, Beijing, Peoples R China [5]Peking Univ, Sch Basic Med Sci, Dept Integrat Chinese & Western Med, Beijing, Peoples R China
推荐引用方式(GB/T 7714):
APA:
MLA:

资源点击量:43389 今日访问量:0 总访问量:3120 更新日期:2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持:重庆聚合科技有限公司 地址:成都市人民南路四段55号